Glenmark launches Tavulus® for COPD treatment in Spain

Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company today announced the launch of a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand name Tavulus® in Spain, for the treatment of chronic obstructive pulmonary disease (COPD).

COPD is a long-term condition that causes inflammation in the lungs, damaging the lung tissue and narrowing the airways, all of which make breathing difficult. Studies show that close to 2.5 million people suffer from COPD in Spain.

Tavulus® is expected to provide relief to a large patient population in the country. It is a long-acting bronchodilator that helps to open the airways and makes it easier for air to get in and out of the lungs. It also works to prevent sudden, short-term worsening of COPD symptoms.

Commenting on the launch, Vice President - Business Development of Glenmark Pharmaceuticals Limited, Dr. Jiří Havránek, says, "The goal of COPD treatment has always been to provide quick symptomatic relief to patients, and reduce the risk of exacerbations. Since its launch, we have seen the multiple therapeutic benefits of Tavulus® in other markets, and we are pleased to extend these benefits to patients in Spain. This inhalation therapy has been shown to significantly aid in the daily management of COPD. We hope that it improves both COPD symptoms and quality of life in those who are most affected."

In November 2017, a Glenmark European subsidiary entered into a strategic, exclusive in-licensing arrangement for marketing generic Tiotropium Bromide DPI in Western Europe and the UK. Glenmark is planning subsequent launches of the product across these markets under the brand name Tiogiva® in UK, Ireland, Sweden, Finland and Norway; Tavulus® in Denmark and Netherlands; and Tiotropium Glenmark® in Germany.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 526.80 as compared to the previous close of Rs. 517.25. The total number of shares traded during the day was 134494 in over 2938 trades.

The stock hit an intraday high of Rs. 529.30 and intraday low of 517.05. The net turnover during the day was Rs. 70672861.00.

Shares of Glenmark Pharmaceuticals Limited was last trading in NSE at Rs. 527.10 as compared to the previous close of Rs. 517.35. The total number of shares traded during the day was 1951963 in over 36287 trades.

The stock hit an intraday high of Rs. 529.25 and intraday low of 516.75. The total traded value during the day was Rs. 1026372297.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 COPDTreatment Spain Tavulus TiotropiumBromide